TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Share Price
Certificat
DE000SW7FGL9
| Market Closed - Boerse Frankfurt Warrants 20:49:07 03/07/2024 BST | ||
| 2.62 EUR | +13.91% |
|
| Current month | +19.55% | ||
| 1 month | -15.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 2.63 | +14.35% |
| 02/07/24 | 2.3 | +12.75% |
| 01/07/24 | 2.04 | -7.27% |
| 28/06/24 | 2.2 | +2.80% |
| 27/06/24 | 2.14 | +0.94% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 08:49 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7FGL |
| ISIN | DE000SW7FGL9 |
| Date issued | 08/03/2024 |
| Strike | 1,160 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.42 € |
|---|---|
| Lowest since issue | 1.75 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Certificates
- Certificat
